Catalent and MigVax today announced that they have signed a development agreement to leverage Catalent’s proprietary Zydis® Bio orally disintegrating tablet (ODT) technology for...
OurCrowd portfolio company MigVax Ltd., a startup developing an oral subunit vaccine against COVID-19, has announced promising results from preclinical tests that demonstrated...
Given as drops on the tongue, Galilee-made MigVax could help address complex challenges of getting boosters to millions around the world over coming...
Qiryat Shmona, Israel, June 10, 2021: MigVax Ltd., a startup company developing an oral subunit vaccine against COVID-19, today announced promising results from...
For the past number of months, our global community has been focused on combating COVID-19. During this time of uncertainty, entrepreneurs have adapted...
OurCrowd, a global leader in online capital formation for early-stage ventures, has scheduled the OurCrowd Pandemic Innovation Conference on June 22nd. The virtual...